The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice.

Vulvovaginal candidiasis (VVC) is an infectious disease caused mainly by Candida albicans. Kangfuxin (KFX) is a traditional Chinese medicine preparation made from Periplaneta americana extracts, which promotes wound healing and enhances body immunity and also acts as an antifungal agent. Here, we evaluated the effect of KFX in the treatment of VVC in vitro and in vivo. The minimum inhibitory concentration (MIC50 ) of KFX against C. albicans ranged from 7·65 to 20·57%. In addition, KFX was more efficient than fluconazole (FLC) in inhibiting the drug-resistant C. albicans, and the effect was more intense after 8 h. The KFX treatment also exhibited good activity in vivo. It restored the body weight and reduced the vulvovaginal symptoms in mice induced with VVC. It downregulated the expression of the hyphae-related gene, HWP1, thus inhibiting the growth and development of C. albicans hyphae. It also increased the number of neutrophils and promoted the secretion of interleukin-17A (IL-17A); however, the levels of interleukin-8 (IL-8) and interleukin-1ß (IL-1ß) decreased in mice with VVC. We deduce that KFX effectively treats vaginal candidiasis in two ways: by inhibiting the growth and development of mycelia to reduce colonization of C. albicans and by promoting the secretion and release of IL-17A and neutrophils in high numbers to fight C. albicans infection. This study provides a theoretical basis for the use of KFX for the clinical treatment of VVC.

Artemisia abrotanum L. (Southern Wormwood)-History, Current Knowledge on the Chemistry, Biological Activity, Traditional Use and Possible New Pharmaceutical and Cosmetological Applications.

Artemisia abrotanum L. (southern wormwood) is a plant species with an important position in the history of European and Asian medicine. It is a species famous as a medicinal plant in Central Asia, Asia Minor, and in South-East and Central Europe. The raw materials obtained from this species are Abrotani herba and Abrotani folium. In the traditional European medicine, they have been used successfully most of all in liver and biliary tract diseases, in parasitic diseases in children and as antipyretic medication. In the official European medicine, this plant species is recommended by the French Pharmacopoeia for use in homeopathy. In many European countries, it is used traditionally in allopathy. The latest studies on the biological activity of extracts from the aboveground parts of the plant and/or the leaves, and/or the essential oil have provided evidence of other possible applications related to their antibacterial, antifungal, antioxidant, anticancer, and antiallergic properties. The latest studies have also focused on the repellent activity of the essential oil of this species and the possibility to use it in the prevention of diseases in which insects are the vectors. The main substances obtained from the plant that are responsible for this activity are: the essential oil, coumarins, phenolic acids, and flavonoids. Some of the latest investigations emphasize the large differences in the composition of the essential oil, determined by the geographical (climatic) origin of the plant. A. abrotanum is recommended by the European Cosmetic Ingredients Database (CosIng) as a source of valuable cosmetic ingredients. Additionally, the leaves of this species possess a well-established position in the food industry. This plant species is also the object of biotechnological studies.

Systematic review of oral treatments for seborrheic dermatitis.

Seborrheic dermatitis (SD) is normally treated with topical corticosteroids and antifungals. Oral therapies can be prescribed in severe or unresponsive cases. This review aims to assess the quantity and quality of published reports on oral therapies for SD. MEDLINE and Embase databases and the reference listings of publications were searched for any publication using oral treatment for SD. The quality of the included publications was assessed using a modified 27 item checklist by Downs and Black. Twenty-one publications (randomized controlled trials, open trials and case reports) covering eight oral therapies (itraconazole, terbinafine, fluconazole, ketoconazole, pramiconazole, prednisone, isotretinoin and homeopathic mineral therapy) were identified. Most of the publications investigated oral antifungals and the quality of the evidence was generally low. The clinical efficacy outcome reported varied considerably between the studies, preventing statistical analysis and direct comparison between treatments. However, ketoconazole therapy was associated with more relapses compared with other treatments. Itraconazole dosing regimen for SD was generally 200 mg/day for the first week of the month followed by 200 mg/day for the first 2 days for 2-11 months. Terbinafine was prescribed at 250 mg/day either as a continuous (4-6 weeks) or as an intermittent regimen (12 days per month) for 3 months. Fluconazole has administered daily (50 mg/day for 2 weeks) or weekly (200-300 mg) for 2-4 weeks. Ketoconazole dosing regimen was 200 mg daily for 4 weeks. Finally, a single 200 mg dose of pramiconazole was administered to patients. This review also highlights key areas for consideration when designing future studies.

[The agent Latrodectus and canine paecilomycotic eclampsia as a laboratory model in the survey of treatment for mycoses and parasitic diseases].

The extragent used to prepare a Latrodectus mactans hydrocarbon extract is a multicomponent system composed of alkanes, alkenes, and arenes. More than 100 compounds were identified in the hydrocarbon extract (petroleum). The petroleum matrix of Latrodectus mactans was first obtained to manufacture homeopathic remedies. The authors could prepare the first Russian homeopathic medicine from Latrodectus mactans, which proved to be effective in treating canine eclampsia. Canine experiments provide a rationale for the authors' choice as the only homeopathic remedy among thousand known drugs to treat female eclampsia. It is Latrodectus mactans that is in the list of homeopathic medicines permitted for use in accordance with Order No. 335 (Supplement 2) of the Ministry of Health and Medical Industry of Russia, issued on November 29, 1995. It is manufactured from Latrodectus mactans living in the USA.

[Cardiac involvement in adults with echinococcosis].

Experiments have established that the first target for echinococcus is the liver and lung and that for pathogenic fungi and protozoa is the heart. Adult patients with hepatic hydatid disease complicated by paecilomycosis have been found to have atypical paecilomycosis-associated myocarditis, the treatment of which was developed by the authors, by using antibiotics, fungicides, and homeopathic remedies.

Fusarium proliferatum-induced chronic lip ulcer: successful treatment with itraconazole: a case report.

BACKGROUND: Fusarium species are saprophytic fungi with a worldwide distribution. These fungi cause various infections among immunocompromised patients; however, they can also involve immunocompetent individuals. CASE PRESENTATION: We report a case of a 41-year-old Iranian woman who presented with ulcerative lesions on her lips 10 months ago. She had a long history of anxiety but had no history of classical risk factors such as trauma, cosmetic lip tattoo, burning in her lips, smoking or use of alcohol and opium. A skin biopsy from the lower lip was performed and sent for microbiological examinations. Hyaline septate hyphae were seen on direct microscopy with potassium hydroxide. The clinical specimen was subcultured on sabouraud dextrose agar with chloramphenicol and prepared for antifungal susceptibility testing and molecular identification. Considering the minimum inhibitory concentrations (MIC) for antifungals, itraconazole (100 mg orally twice a day) was started for her, and after 2 months, the lesions were treated. She followed up for 3 months, and no signs of disease recurrence were observed. CONCLUSIONS: Selecting an appropriate treatment strategy according to the laboratory assessments is essential in clinical practice and the management of rare infections to prevent related mortality and morbidity of opportunistic fungal infections.

Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial.

OBJECTIVE: Antimycotics effectively treat sporadic and recurrent vulvovaginal candidiasis (RVVC). Classic homeopathy (CH) is also used to treat this condition. We compared the efficacy of CH and itraconazole in reducing the frequency of RVVC episodes. DESIGN: Single-centre, prospective, randomised trial. SAMPLE: One hundred-and-fifty patients with a history of RVVC and an acute episode of VVC. METHODS: Women were randomised into 3 groups: itraconazole with lactobacilli (group 1), itraconazole without lactobacilli (group 2) and CH (group 3). Itraconazole treatment of acute infection was followed by a 6-month maintenance regimen with monthly single-day itraconazole (200 mg bid). Women in group 1 were given additional vaginal lactobacilli for 6 days per month throughout the maintenance regimen Thereafter, patients were followed without treatment for 6 months. CH treatment was performed for 12 months. RESULTS: Women in groups 1 and 2 reached a culture-free status significantly earlier than women in group 3 (log-rank test; P < 0.0001). Specifically, before the start of the maintenance regimen, 44 of 49 women (89.8%) in group 1 and 40 of 47 women (85%) in group 2 were free of Candida detectable by culture, 22 of 46 (47%) women in group 3 reached a culture-free status after the first visit, but had a recurrence significantly earlier compared with women in groups 1 and 2 (log-rank test; P = 0.002). After 12 months, 19 of 25 (76%) women in group 1, 18 of 23 (78%) women in group 2 and 9 of 23 (39%) women in group 3 were free of culture-detectable Candida. Assessment of RVVC-associated complaints by VAS score showed that women in group 3 had a significantly higher level of discomfort (36.8, 25.1 and 27.7 respectively; P < 0.001) and were significantly less satisfied (59.2, 68.2 and 71.7 respectively; P < 0.001) than patients in groups 1 and 2. CONCLUSIONS: Monthly cycle-dependent itraconazole is more effective than CH in the treatment of RVVC. Lactobacilli do not confer an added benefit.

Treatment of seborrheic dermatitis: a comprehensive review.

Seborrheic dermatitis (SD) is a chronic, recurring inflammatory skin disorder that manifests as erythematous macules or plaques with varying levels of scaling associated with pruritus. The condition typically occurs as an inflammatory response to Malassezia species and tends to occur on seborrheic areas, such as the scalp, face, chest, back, axilla, and groin areas. SD treatment focuses on clearing signs of the disease; ameliorating associated symptoms, such as pruritus; and maintaining remission with long-term therapy. Since the primary underlying pathogenic mechanisms comprise Malassezia proliferation and inflammation, the most commonly used treatment is topical antifungal and anti-inflammatory agents. Other broadly used therapies include lithium gluconate/succinate, coal tar, salicylic acid, selenium sulfide, sodium sulfacetamide, glycerin, benzoyl peroxide, aloe vera, mud treatment, phototherapy, among others. Alternative therapies have also been reported, such as tea tree oil, Quassia amara, and Solanum chrysotrichum. Systemic therapy is reserved only for widespread lesions or in cases that are refractory to topical treatment. Thus, in this comprehensive review, we summarize the current knowledge on SD treatment and attempt to provide appropriate directions for future cases that dermatologists may face.

Acute pancreatitis in a patient treated with micafungin.

CASE SUMMARY: A 73-year-old man (height, 158.2 cm; weight, 49.8 kg) presented with upper abdominal tenderness after 3 weeks of treatment with 150 mg/d of micafungin (3 mg/kg . d) (Mycamine, Astellas Pharma US Inc., Deerfield, Illinois) intravenously for pulmonary aspergillosis accompanied by [DOSAGE ERROR CORRECTED] pulmonary Mycobacterium avium complex (MAC) infection. Pulmonary aspergillosis was noninvasively diagnosed by a fungus lump in a cavity in the right upper lung field with a high value of 1,3-beta-D-glucan and a positive result for aspergillosis antigen. The patient had a medical history of gastrectomy due to gastric cancer and idiopathic thrombocytopenic purpura (ITP). He had been prescribed 800 mg/d of clarithromycin, 400 mg/dL of rifampicin, and 750 mg/d of ethambutol hydrochloride for pulmonary MAC infection for 2 years and 5 mg/d of prednisolone for ITP for 7 years. No traditional or homeopathic medicine had been received/administered. Laboratory tests at the onset of abdominal pain revealed a white blood cell count of 4300/microL with 51% neutrophils. There was no eosinophilia. Platelet count was 15,100/muL, with normal coagulation. Immunoglobulin G and immunoglobulin M were 1720 and 154 mg/dL, respectively. The patient had no history of allergy, biliary tract disease, hyperlipidemia, or hypercalcemia. He did not report alcohol use. The laboratory findings, magnetic resonance imaging, and upper abdominal tenderness were consistent with acute pancreatitis. After cessation of all drugs, his symptoms improved with bowel rest and parenteral nutrition. His laboratory measurements normalized thereafter. All drugs, except micafungin, were readministered for pulmonary MAC infection and ITP, and itraconazole was administered for pulmonary aspergillosis after the recovery from pancreatitis. During 16 months of follow-up, the pancreatitis did not recur. DISCUSSION: We performed a literature search of all available English-language articles published on MEDLINE between January 1966 and January 2007 using the key terms micafungin (text and indexed terms) and pancreatitis (text and indexed terms). Based on the search of MEDLINE, there have been no reports of acute pancreatitis associated with micafungin. The Naranjo adverse drug reaction (ADR) probability scale was used to assess the probability of micafungin-associated acute pancreatitis. A score of 6 was obtained, indicating a probable ADR from micafungin treatment. CONCLUSION: We report a case of acute pancreatitis probably associated with micafungin use in an elderly patient.

Vaginitis: making sense of over-the-counter treatment options.

BACKGROUND: The FDA approved over-the-counter (OTC) use of vaginal antifungals in 1990. Subsequently, a plethora of OTC products have become available to women on drugstore shelves. OBJECTIVES: The purpose of this study was to determine the availability of OTC products marketed for the treatment of vaginitis and to determine if their efficacy had been confirmed by published prospective randomized control trials (RCTs). MATERIALS AND METHODS: The authors chose four retail locations frequented by women seeking vaginitis treatment. All products deemed a viable treatment option were purchased. Results. All intravaginal imidazoles purchased, regardless of treatment duration or active ingredient, were found to be of proven efficacy. We were unable to find an RCT confirming the effectiveness of vaginal anti-itch creams and homeopathic treatments for vaginitis. CONCLUSION: 45% of products available to women in the feminine hygiene section of the stores surveyed could not be confirmed to be effective for treating infectious vaginitis.

[Clinical and experimental studies on composite divitriol infusion in treating tinea manum].

OBJECTIVE: To investigate the effect of Composite Divitriol Infusion (CDI) in treating tinea manum and studying its antimycotic action. METHODS: CDI was used to treat 139 patients with tinea manum. The experimental study in vivo was done, scanning electron microscopy (SEM) was used to observe the therapeutical effect of CDI. RESULTS: One hundred and four cases among the 139 patients were cured, 21 were markedly effective, 10 improved and 4 ineffective, the effective rate being 89.9%. Between CDI group and the control group, there was a very significant difference (chi 2 > 12.84, P < 0.005). The antimycotic action of CDI was studied in vitro. Its minimum inhibitory concentrations (MIC) of CDI were about 0.25% for Trichophyton rubrum, and 0.5% for Trichophyton gypseum and Microsporum gypseum. Trichophyton rubrum immersed with CDI show that the mycelia became roughened, deformed and macroconidum became smaller under SEM. CONCLUSION: CDI is valuable in treating tinea manum.

[Observation of cell ultrastructuse in suppurative otitis media treated with bosneol and application].

OBJECTIVE: To explore the pharmacological action and optimal concentration of borneol in treating suppurative otitis media. METHOD: Aspergillus niger separated from the secretion in external auditory canal of the patient and the fungus strains kept in the laboratory were used to determine the minimum fungus inhibiting concentration (MIC) and minimum fungus killing concentration (MFC) of borne. The change of cell ultrastructure after borneol taking effect was observed under electron microscope. RESULT: Borneol MIC and MFC turned out to be 5% and 10% respectively. The cell wall of Aspergillus niger became thicker and blurred with vacuoles. In the cytoplasm various materials were found deep dyed and agglutinated with many fat drops. The electron density increased and the ridge arrangement was in disorder. Some organelles were destroyed, and many areas of electron blank appeared. Some cells became warped and deformed and lost their original structure. CONCLUSION: Borneol can destroy the structure of fungus cells, make fungus dissolve and dieout and thus features a fungus inhibiting and killing function. The optimal inhibiting concentration is 5% and killing concentration 10%.

Lufenuron no tratamento da dermatofitose em gatos? / Treatment of dermatophytosis in cats with lufenuron?

Due to discrepancies regarding the effectiveness of lufenuron in treating dermato-phytosis caused by Microsporum canis the effect of this drug was checked in 46 cats (30 with cutaneous lesions and 16 asymptomatic carriers) treated in the Veterinary Hospital of the Federal Rural University of Rio de Janeiro, Brazil. The diagnosis was based on Wood's lamp examination and fungal cultures. Biopsies were only performed in symptomatic animals. The animals were treated with lufenuron (120mg/kg every 21 days), for 4 times. The drug was efficient in 29 of the 30 affected felines and as well as in all of the asymptomatic carriers. The cat that did not respond, had received several dexameta-zone doses prior to the treatment with lufenuron. The drug was given to one animal during the first stages of pregnancy and no abnormalities or neonatal disorders were found in any of the kittens. None of the treated animals showed side effects. Twenty days after the last administration of lufenuron, 45 of the studied animals (98 percent) had negative fungal culture. The cost of treating dermatophytosis with lufenuron is a little higher than with ketoconazole, but the drug has some advantages regarding its practicability and security.The correct drug prescription and animal's medication as well as environmental decontamination are very important for the success of the treatment.

Em função de controvérsias sobre a eficácia do lufenuron no tratamento da dermatofitose causada por Microsporum canis, o efeito da droga foi avaliado em 46 gatos (30 com lesões cutâneas e 16 portadores assintomáticos) atendidos no Hospital Veterinário da Universidade Federal Rural do Rio de Janeiro, Brasil. O diagnóstico foi estabelecido através da lâmpada de Wood, da cultura fúngica e, adicionalmente, na maioria dos animais sintomáticos, pela avaliação histopatológica da pele. Os animais foram tratados com 120mg/kg de lufenuron, a cada 21 dias (quatro doses); a droga mostrou-se eficaz no tratamento de 29 dos 30 felinos que apresentaram a forma clínica da dermatofitose, bem como no de todos os animais assintomáticos. O único felino que não teve cura clínica completa havia recebido várias doses de dexametasona antes do inicio do tratamento. Em um animal gestante, foram utilizadas duas doses do lufenuron e não foi observada qualquer alteração clínica e morfológica nos filhotes. Nenhum dos animais tratados teve qualquer reação adversa ao medicamento. Vinte dias após o último tratamento, o exame micológico resultou negativo em 45 dos felinos estudados (98 por cento). Embora o lufenuron tenha o custo um pouco mais elevado do que o do cetoconazol, é uma droga que apresenta praticidade e margem de segurança bem maiores. Vale ressaltar que o sucesso do tratamento está diretamente relacionado à correta utilização da droga, assim como a perfeita higienização do ambiente e dos utensílios dos animais.

Tratamiento de la coccidioidomicosis experimental en ratas Wistar / Experimental treatment of coccidioidomycosis in Wistar rats

Se realizó un estudio comparativo entre Itraconazol (I) y Fluconazol (F) en el tratamiento de la coccidioidomicosis experimental en ratas Wistar. Treinta animales de 250 g de peso fueron inoculados con 200 artroconidias de Coccidioides immitis por vía intercardíaca. Ambas drogas fueron administradas por gastroclisis a razón de 200 mg//kg/día durante 5 semanas a partir del 7 día post-inoculación. El grupo control recibió el solvente de las drogas. Los animales que sobrevivieron 2 semanas después de concluído el tratamiento fueron sacrificados y se le realizaron los siguientes estudios: 1) examen macroscópico (presencia de granulomas) y microscópico (presencia de esporangios) en los pulmones; 2) unidades formadoras de colonias en homogeneizado de pulmones; 3) estudio histopatológico de pulmones con H & E realizando una evaluación semi-cuantitativa contando: a) número de granulomas por campo de 50x; b) número de esporangios con esporangiosporos en cada granuloma y c) número de esporangios vacíos. Los resultados obtenidos mostraron que el itraconazol fue más eficaz que el fluconazol en el tratamiento de este modelo experimental, en la evaluación efectuada a través de varios de los parámetros considerados: 1) se comprobaron menor cantidad de cultivos pulmonares positivos, (30 por ciento vs 100 por ciento); 2) menor número de UFC/g de pulmón (<1x10 vs 1.7x10 ); 3) menos cantidad de granulomas pulmonares en el estudio histopatológico (1/14 campos vs 1/4 campos); 4) menor cantidad de esporangios por granuloma (0 vs 33) y 5) mayor número de esporangios vacíos o alterados. Cabe señalar, sin embargo, que el fluconazol fue capaz de reducir el número de UFC/g pulmón,comparando con el grupo control

Eficacia de itraconazol en dermatomicosis: comparación de dos esquemas posológicos con método doble ciego / Itraconazole efficacy in dermatomycoses

A 40 enfermos con dermatomicosis se les administraron dos esquemas posológicos de itraconazol (100 mg./día-14 días: grupo A - y 200 mg./día - 7 días: grupo B) seleccionados por el método de doble ciego. De los 37 enfermos evaluados (hubo 3 abandonos) el 100 por ciento obtuvo mejoría significativa o remisión clínica completa (en ambos grupos igual respuesta). Los estudios micológicos microscópicos directos fueron negativos en el 65 por ciento de los casos (grupo A: 32,5 por ciento - grupo B: 32,5 por ciento) al finalizar el tratamiento y los cultivos se negativizaron en el 86,4 por ciento de los pacientes (grupo A: 43,2 por ciento - grupo B: 43,2 por ciento). No se demostró diferencia significativa con los dos esquemas posológicos ensayados